Tripos to Build One of the Leading Informatics-Driven Drug Discovery Laboratories in Europe

- State-of-the-Art Chemical Synthesis Facilities to be Built in Cornwall, England -

29-Apr-2002

ST. LOUIS, MO - April 25, 2002 - Responding to worldwide demand by pharmaceutical and biotechnology companies to accelerate timelines in the discovery of new drugs and therapeutics for the marketplace, the leading provider of drug discovery chemistry, software and enterprise informatics, Tripos, Inc., today announced it will significantly expand its Tripos Receptor Research facility and intends to considerably increase its workforce, in Bude, Cornwall, England. The new facility will more than double Tripos' current chemistry laboratories to 65,000 sq. ft., expand its personnel to 230 people, and is expected to be fully operational in early 2004.

This significant expansion will provide Tripos with the scientific staff and infrastructure to meet the growing demand for its informatics-driven discovery research products and services, including the recently announced four-year, $100 million agreement with pharmaceutical giant Pfizer to design, synthesize and purify high-quality, drug-like compounds to expand their high-throughput screening compound collection.

Tripos Receptor Research is a premiere scientific research facility that uses proprietary information-driven technologies to enhance the efficient design and synthesis of chemical compound libraries. These highly-focused LeadQuest® libraries are used around the world by leading drug discovery companies such as Pfizer, Lipha S.A. (the French subsidiary of Merck KgA), and others to identify promising new drug candidates. Tripos' drug discovery services include refinement (or optimization) processes for the compounds that demonstrate desired biological activity against the defined drug target. Known for problem solving, Tripos technologies rescue stalled discovery projects and navigate around patented chemical space to quickly move discovery projects forward for its customers.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...

Last viewed contents

CIM® Monolithic Well Plates | Multiwell plates | Sartorius

CIM® Monolithic Well Plates | Multiwell plates | Sartorius

Max-Planck-Institut für experimentelle Medizin - Göttingen, Germany

Max-Planck-Institut für experimentelle Medizin - Göttingen, Germany

Max-Planck-Institut für Kolloid- und Grenzflächenforschung - Potsdam, Germany

Max-Planck-Institut für Kolloid- und Grenzflächenforschung - Potsdam, Germany

Truffini & Reggè Farmaceutici S.r.l. - Mailand, Italy

Truffini & Reggè Farmaceutici S.r.l. - Mailand, Italy

Leibniz-Institut für Pflanzengenetik und Kulturpflanzenforschung (IPK Gatersleben) - Gatersleben, Germany

Leibniz-Institut für Pflanzengenetik und Kulturpflanzenforschung (IPK Gatersleben) - Gatersleben, Germany

From beer to useful fats and medicines - The spent grain from beer brewing can be used to make microcapsules that can preserve omega-3 oils and medicines

From beer to useful fats and medicines - The spent grain from beer brewing can be used to make microcapsules that can preserve omega-3 oils and medicines

Simtra BioPharma Solutions - Parsippany, USA

Simtra BioPharma Solutions - Parsippany, USA

Ancient viral DNA shapes modern human placentas - “It’s a reminder that there is much more to learn about our genome and how ancient infections can influence who we are today”

Ancient viral DNA shapes modern human placentas - “It’s a reminder that there is much more to learn about our genome and how ancient infections can influence who we are today”

Chemistry meets biology: controlling artificial cell membranes through catalysis - Researchers develop an artificial metalloenzyme-based platform that enables programmable control of artificial membrane behavior

Chemistry meets biology: controlling artificial cell membranes through catalysis - Researchers develop an artificial metalloenzyme-based platform that enables programmable control of artificial membrane behavior

Merck Invests €70 million to Expand ADC Manufacturing for Novel Cancer Therapies - Triples manufacturing capacity to meet increased global demand for antibody-drug conjugates (ADCs)

Merck Invests €70 million to Expand ADC Manufacturing for Novel Cancer Therapies - Triples manufacturing capacity to meet increased global demand for antibody-drug conjugates (ADCs)

StratifAI Raises €12.5M for Clinical Validation of AI Biomarker Platform for Precision Oncology - Oversubscribed round expand global reach, and unlock multi‑billion‑euro cancer diagnostics market

StratifAI Raises €12.5M for Clinical Validation of AI Biomarker Platform for Precision Oncology - Oversubscribed round expand global reach, and unlock multi‑billion‑euro cancer diagnostics market

New deep-learning tool can tell if your salmon is wild or farmed

New deep-learning tool can tell if your salmon is wild or farmed